deltatrials
Enrolling By Invitation PHASE3 INTERVENTIONAL 2-arm NCT06801886

Silymarin's Advantage on Graft Effectiveness (SAGE)

Effect of Silymarin Supplementation on Graft Function and Early Post-transplant Complications

Sponsor: University Hospital, Martin

Conditions Acute Graft Rejection Antibody Mediated Rejection of Kidney Transplant Arterial Hypertension, Chronic Kidney Disease Biopsy Proven Acute Rejection Posttransplant Diabetes Mellitus
Interventions Placebo Supplementation Silymarine supplementation
Updated 2 times since 2025 Last updated: Mar 25, 2025 Started: Jan 7, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Graft Rejection and Antibody Mediated Rejection of Kidney Transplant, this trial is ongoing. The trial is conducted by University Hospital, Martin and has accumulated 2 data snapshots since 2020. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshotEnrolling By Invitation~Apr 2025 – present · 15 months · monthly snapshotEnrolling By Invitation

Change History

2 versions recorded

  1. Apr 2025 — Present [monthly]

    Enrolling By Invitation PHASE3

  2. Feb 2025 — Apr 2025 [monthly]

    Enrolling By Invitation PHASE3

    First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University Hospital, Martin
Data source: University Hospital, Martin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations